INFLARX NV (IFRX) Stock Price, Quote, News and Overview
NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD
IFRX Quote, Performance and Key Statistics
1.85
+0.03 (+1.65%)
The current stock price of IFRX is 1.85 USD. In the past month the price increased by 42.31%. In the past year, price increased by 28.47%.
IFRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About IFRX
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Company Info
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
INFLARX NV / IFRX FAQ
What is the stock price of INFLARX NV today?
The current stock price of IFRX is 1.85 USD. The price increased by 1.65% in the last trading session.
What is the ticker symbol for INFLARX NV stock?
The exchange symbol of INFLARX NV is IFRX and it is listed on the Nasdaq exchange.
On which exchange is IFRX stock listed?
IFRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INFLARX NV stock?
13 analysts have analysed IFRX and the average price target is 9.52 USD. This implies a price increase of 414.59% is expected in the next year compared to the current price of 1.85. Check the INFLARX NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INFLARX NV worth?
INFLARX NV (IFRX) has a market capitalization of 124.19M USD. This makes IFRX a Micro Cap stock.
How many employees does INFLARX NV have?
INFLARX NV (IFRX) currently has 74 employees.
What are the support and resistance levels for INFLARX NV (IFRX) stock?
INFLARX NV (IFRX) has a support level at 1.65 and a resistance level at 1.85. Check the full technical report for a detailed analysis of IFRX support and resistance levels.
Is INFLARX NV (IFRX) expected to grow?
The Revenue of INFLARX NV (IFRX) is expected to decline by -45.24% in the next year. Check the estimates tab for more information on the IFRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INFLARX NV (IFRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IFRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IFRX, evaluating the profitability, health, valuation and growth aspects
- INFLARX NV (IFRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INFLARX NV (IFRX) Sales and EPS estimates to see what analysts future expectations are.
- INFLARX NV (IFRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INFLARX NV (IFRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- INFLARX NV (IFRX) Stock Chart to make your own analysis
- INFLARX NV (IFRX) Latest news and press-releases to stay up to date.
Does INFLARX NV (IFRX) stock pay dividends?
IFRX does not pay a dividend.
When does INFLARX NV (IFRX) report earnings?
INFLARX NV (IFRX) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of INFLARX NV (IFRX)?
INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
What is the Short Interest ratio of INFLARX NV (IFRX) stock?
The outstanding short interest for INFLARX NV (IFRX) is 1.8% of its float. Check the ownership tab for more information on the IFRX short interest.
IFRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IFRX. When comparing the yearly performance of all stocks, IFRX is one of the better performing stocks in the market, outperforming 86.34% of all stocks.
IFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX has a bad profitability rating. Also its financial health evaluation is rather negative.
IFRX Financial Highlights
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -5.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.4% | ||
| ROE | -63.47% | ||
| Debt/Equity | 0 |
IFRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to IFRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 0.37% and a revenue growth -45.24% for IFRX